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Combined SIRT3 and SIRT5 
deletion is associated with inner 
retinal dysfunction in a mouse 
model of type 1 diabetes
Jonathan B. Lin1,2, Joseph B. Lin1, Howard C. Chen1, Teresa Chen1 & Rajendra S. Apte1,2,3,4
Diabetic retinopathy (DR) is a major cause of blindness in working adults in the industrialized world. 
In addition to vision loss caused by macular edema and pathological angiogenesis, DR patients 
often exhibit neuronal dysfunction on electrophysiological testing, suggesting that there may be an 
independent neuronal phase of disease that precedes vascular disease. Given the tremendous metabolic 
requirements of the retina and photoreceptors in particular, we hypothesized that derangements 
in metabolic regulation may accelerate retinal dysfunction in diabetes. As such, we induced 
hyperglycemia with streptozotocin in mice with monoallelic Nampt deletion from rod photoreceptors, 
mice lacking SIRT3, and mice lacking SIRT5 and tested multiple components of retinal function with 
electroretinography. None of these mice exhibited accelerated retinal dysfunction after induction of 
hyperglycemia, consistent with normal-appearing retinal morphology in hyperglycemic Sirt3−/− or 
Sirt5−/− mice. However, mice lacking both SIRT3 and SIRT5 (Sirt3−/−Sirt5−/− mice) exhibited significant 
evidence of inner retinal dysfunction after induction of hyperglycemia compared to hyperglycemic 
littermate controls, although this dysfunction was not accompanied by gross morphological changes 
in the retina. These results suggest that SIRT3 and SIRT5 may be involved in regulating neuronal 
dysfunction in DR and provide a foundation for future studies investigating sirtuin-based therapies.
Diabetic retinopathy (DR) is a major cause of blindness in working adults in the industrialized world1. Patients 
with early-stage disease can exhibit non-proliferative DR, which consists of initial pericyte loss and microan-
eurysms, followed by capillary wall damage and retinal edema or hemorrhages. If it is left untreated, prolifer-
ative DR ensues, leading to hypoxic pathologic neovascularization and further vision loss. Current therapeutic 
strategies for DR target vascular endothelial growth factor (VEGF)2. While anti-VEGF therapies have greatly 
improved treatment outcomes, they are not always effective and are sometimes associated with adverse events3–7. 
Importantly, anti-VEGF therapies do not address the possibility that neuroretinal dysfunction may contribute to 
vision loss independently from vascular disease. If there is indeed independent neuronal disease, current thera-
pies directed against pathological angiogenesis leave this retinal neuron death completely unabated. Some groups 
have also suggested that prolonged VEGF blockade in the retina may affect the neuroprotective functions of 
VEGF that are important in retinal physiology8,9, although not all studies are in agreement10.
In support of the possibility of an independent neuronal component of disease, there have been numerous 
reports that DR patients exhibit early deficits on electrophysiological testing, such as delayed implicit times and 
decreased oscillatory potential amplitudes, observed prior to any evidence of vascular dysfunction11–15. Moreover, 
other studies have found that various rodent models of diabetes, including high-fat diet-induced metabolic dys-
function and streptozotocin (STZ)-induced hyperglycemia, also exhibit electrophysiological changes that are 
indeed suggestive of retinal neuron dysfunction independent from vascular disease14,16,17. Therefore, there is a 
great need not only to characterize the neuroretinal dysfunction associated with DR but also to identify the 
underlying pathogenic mechanisms to facilitate the discovery of novel approaches for targeted interventions.
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Past studies have shown that, in the STZ-induced model of diabetes, prolonged systemic hyperglycemia leads 
to retinal oxidative stress and retinal mitochondrial damage, which ultimately cause retinal neuron death18–20. 
Therefore, we hypothesized that impaired mitochondrial function broadly contributes to retinal neurodegenera-
tion in DR. This hypothesis is consistent with the fact that the retina and photoreceptors in particular have high 
bioenergetic demands not only to maintain a constant dark current but also to meet their anabolic needs due to 
constant membrane turnover, which limit their capacity to tolerate metabolic perturbations21,22.
Since we recently demonstrated that NAMPT-mediated NAD+ biosynthesis, SIRT3, and SIRT5 all play impor-
tant roles in maintaining retinal energetic homeostasis23, we hypothesized that these pathways may also play 
neuroprotective roles in DR. In this study, we investigated whether partially disrupting NAMPT-mediated NAD+ 
biosynthesis or deleting SIRT3/SIRT5 would accelerate early neuroretinal dysfunction in the STZ-induced mouse 
model of type 1 diabetes. In contrast with our hypothesis, we found that abrogating these pathways individually 
did not accelerate neuroretinal dysfunction in mice based on any of the electrophysiological parameters that 
we tested. On the other hand, mice lacking both SIRT3 and SIRT5 exhibited significantly more inner retinal 
Figure 1. (a) Mice with monoallelic Nampt deletion from rod photoreceptors (Nampt−rod/WT; N = 7) were 
similarly susceptible to streptozotocin (STZ)-induced hyperglycemia compared to NamptF/WT controls (N = 4; 
2-tailed, unpaired t-test). (b–d) At 11 weeks after STZ induction, Nampt−rod/WT mice (N = 6–7) did not exhibit 
any signs of retinal dysfunction compared to NamptF/WT controls (N = 4) based on their scotopic a-wave, 
scotopic b-wave, or photopic b-wave amplitudes (2-way mixed ANOVA). (e,f) At 6 weeks after STZ induction 
in wild-type (WT) mice, there were no changes in retinal SIRT3 or SIRT5 protein levels as measured by 
immunoblotting shown in (e) with quantifications shown in (f). Open circles depict individual mice (a); graphs 
depict mean ± S.E.M. (b–d) or mean + S.E.M. (f) Each lane represents an individual mouse; the entire gel is 
depicted without splicing or cropping (e).
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dysfunction following induction of hyperglycemia compared to hyperglycemic littermate controls. Together, 
these findings suggest that SIRT3 and SIRT5 may have potential redundant neuroprotective roles in a mouse 
model of type 1 DR.
Figure 2. (a,b) SIRT3 germline knockout (Sirt3−/−) mice (N = 8–9/group) were similarly susceptible to 
streptozotocin (STZ)-induced hyperglycemia compared to wild-type (Sirt3+/+) controls (N = 10–12/group). 
(c,d) SIRT5 germline knockout (Sirt5−/−) mice (N = 7–13/group) were similarly susceptible to STZ-induced 
hyperglycemia compared to wild-type (Sirt5+/+) controls (N = 5–8/group). (e,f) Sirt3+/+ and Sirt3−/− mice 
(N = 8–12/group) had similar patterns of weight gain after STZ induction. (g,h) Sirt5+/+ and Sirt5−/− mice 
(N = 5–13/group) had similar patterns of weight gain after STZ induction. Open circles depict individual mice 
(a–h).
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Results
Monoallelic Nampt deletion in rod photoreceptors does not accelerate retinal dysfunction in a 
mouse model of type 1 diabetes. Biallelic Nampt deletion in rod or cone photoreceptors leads to rapid 
retinal degeneration that is complete by 6 weeks of age23. However, monoallelic, rod-specific Nampt deletion 
does not lead to significant retinal degeneration as late as six months of age24, although this does not rule out the 
possibility that Nampt becomes essential under conditions of metabolic stress, such as in diabetes. Therefore, we 
sought to determine whether monoallelic Nampt deletion in rod photoreceptors (Nampt−rod/WT) would render 
rod photoreceptors more vulnerable to degeneration in a mouse model of type 1 diabetes. Both Nampt−rod/WT  
mice and their Cre-negative controls (NamptF/WT) were equally susceptible to STZ-induced hyperglycemia 
(Fig. 1a). We tested the retinal function of these mice with electroretinography (ERG) 11 weeks after STZ induc-
tion. We found that there were no significant differences in scotopic a-wave, scotopic b-wave, or photopic b-wave 
Figure 3. (a–f) At 11 weeks after streptozotocin (STZ) induction, hyperglycemic SIRT3 germline knockout 
(Sirt3−/−) mice had significant retinal dysfunction based on their scotopic a-wave, scotopic b-wave, and 
photopic b-wave amplitudes compared to normoglycemic mice of the same genotype (N = 8–9/group; 2-way 
mixed ANOVA with Bonferroni post-hoc test). Hyperglycemic wild-type (Sirt3+/+) mice also exhibited similar 
retinal dysfunction compared to normoglycemic controls of the same genotype (N = 11–12/group; 2-way 
mixed ANOVA with Bonferroni post-hoc test). (g–l) At 11 weeks after STZ induction, hyperglycemic SIRT5 
germline knockout (Sirt5−/−) and wild-type (Sirt5+/+) mice did not exhibit any retinal dysfunction compared 
to normoglycemic controls of the same genotype (N = 8–13/group; 2-way mixed ANOVA). Graphs depict 
mean ± S.E.M. (a–l) (*P < 0.05; **P < 0.01; ***P < 0.001; ^P < 0.0001).
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amplitudes (Fig. 1b–d). These findings suggest that monoallelic Nampt deletion in rod photoreceptors does not 
make mice more susceptible to retinal neurodegeneration in a model of type 1 diabetic retinopathy. Thus, Nampt 
is haplosufficient in this disease context.
SIRT3 and SIRT5 individually play minimal neuroprotective roles in a mouse model of type 1 
diabetes. The fact that monoallelic Nampt deletion did not accelerate retinal neurodegeneration in a mouse 
model of type 1 diabetes does not completely rule out the possibility that SIRT3 and SIRT5, downstream sensors 
of NAD+ availability, may still play a role in DR. Because past studies have demonstrated that chronic systemic 
hyperglycemia induces mitochondrial damage18–20, we first evaluated whether there is increased SIRT3 or SIRT5 
protein expression in retinas from STZ-induced hyperglycemic, wild-type mice. SIRT3 and SIRT5 were not indi-
vidually upregulated at the protein level in retinas from hyperglycemic mice compared to those from normogly-
cemic controls (Fig. 1e,f).
To test whether SIRT3 or SIRT5 exert a neuroprotective role under hyperglycemic conditions, we character-
ized whether germline deletion of Sirt3 or Sirt5 caused early neuroretinal dysfunction in a mouse model of type 1 
diabetes. We found that mice lacking Sirt3 (Sirt3−/−) or Sirt5 (Sirt5−/−) were equally susceptible to STZ-induced 
hyperglycemia compared to wild-type controls (Fig. 2a–d). Moreover, all mice, regardless of genotype or glycemic 
status, had similar patterns of weight gain over time (Fig. 2e–h), suggesting a similar systemic burden of disease. 
When we tested retinal function with ERG, we found that hyperglycemic Sirt3+/+ and Sirt3−/− mice exhibited 
modest retinal dysfunction compared to their normoglycemic controls in their scotopic a-wave, scotopic b-wave, 
and photopic b-wave amplitudes (Fig. 3a–f). However, of interest, the magnitude of this difference between STZ- 
and vehicle-treated mice was similar for both genotypes, suggesting a minimal neuroprotective role for SIRT3. In 
contrast, hyperglycemic Sirt5+/+ and Sirt5−/− mice did not exhibit retinal dysfunction compared to their normo-
glycemic controls in their scotopic a-wave, scotopic b-wave, or photopic b-wave amplitudes (Fig. 3g–l).
In agreement with this electrophysiological characterization showing similar and only moderate 
hyperglycemic-induced changes in retinal function between Sirt3+/+ and Sirt3−/− mice, we found no gross differ-
ences in retinal morphology between these mice upon histological examination (Fig. 4). Similarly, there were no 
gross morphological changes between Sirt5+/+ and Sirt5−/− retinas, regardless of whether they were from normo- 
or hyperglycemic mice (Fig. 4). These data suggest that SIRT3 and SIRT5 individually play only minimal, if any, 
neuroprotective roles under conditions of hyperglycemia.
Since past reports have suggested that mouse models of DR may exhibit subtle changes in ERG responses, we 
also assessed whether there were any changes in a- or b-wave implicit times. We did not find any significant differ-
ences in scotopic a- or b-wave implicit times in hyperglycemic versus normoglycemic Sirt3+/+ and Sirt3−/− mice 
Figure 4. Representative histological images demonstrate that there were no changes in retinal morphology 
upon germline deletion of either SIRT3 or SIRT5, regardless of whether the mice were normo- or 
hyperglycemic.
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(Fig. 5a–d). Photopic b-wave implicit times were mildly reduced when comparing hyperglycemic Sirt3+/+ mice 
to normoglycemic Sirt3+/+ mice (main effectSTZ: P = 0.0135; Fig. 5e). Although not statistically significant, hyper-
glycemic versus normoglycemic Sirt3−/− mice showed a similar magnitude of change in photopic b-wave implicit 
times, arguing for a minimal neuroprotective role for SIRT3 (Fig. 5f). Likewise, except for one pairwise compar-
ison after post-hoc testing, there were no significant differences in scotopic a-wave, scotopic b-wave, or photopic 
b-wave implicit times in hyperglycemic Sirt5+/+ or Sirt5−/− mice compared to normoglycemic mice of the same 
genotype (Fig. 6a–f). These data suggest, once again, that SIRT5 plays a minimal neuroprotective role.
We next evaluated oscillatory potential (OP) amplitudes, which may reveal inner retinal dysfunction. There 
were no significant differences of appreciable effect size in scotopic OP amplitudes between hyperglycemic 
Sirt3+/+ and Sirt3−/− mice and normoglycemic mice of the same genotype, except for one pairwise comparison 
at a single flash intensity after post-hoc testing (Fig. 7a,b). Although photopic OP amplitudes were significantly 
increased in hyperglycemic versus normoglycemic Sirt3−/− mice (main effectSTZ: P = 0.0113), we observed a sim-
ilar pattern in hyperglycemic versus normoglycemic Sirt3+/+ mice (main effectSTZ: P = 0.0051) (Fig. 7c,d). Finally, 
there were no differences in scotopic or photopic OPs in hyperglycemic Sirt5+/+ and Sirt5−/− mice compared to 
normoglycemic mice of the same genotype (Fig. 7e–h). Together, these findings further support our assertion that 
SIRT3 and SIRT5 individually play minimal neuroprotective roles in a mouse model of DR.
Combined SIRT3 and SIRT5 deletion is associated with inner retinal dysfunction in a mouse 
model of type 1 diabetes. Numerous past studies have suggested that SIRT3 and SIRT5 may have some 
degree of redundancy since they are both mitochondrial deacylases with many of the same protein targets25,26. 
Moreover, we have previously reported that although mice lacking both SIRT3 and SIRT5 do not exhibit retinal 
degeneration at baseline, they are more vulnerable to light-induced degeneration23. Therefore, we sought to deter-
mine whether combined deletion of both SIRT3 and SIRT5 may render mice more susceptible to retinal dysfunc-
tion in a model of type 1 diabetes. Mice lacking both SIRT3 and SIRT5 (Sirt3−/−Sirt5−/−) were equally susceptible 
to STZ-induced hyperglycemia compared to control littermates of various genotypes, including Sirt3+/−Sirt5+/−, 
Figure 5. (a–d) There were no significant differences in the scotopic a- or b-wave implicit times when 
comparing hyperglycemic SIRT3 germline knockout (Sirt3−/−) and wild-type control (Sirt3+/+) mice to 
normoglycemic mice of the same genotype (N = 8–12/group; 2-way mixed ANOVA). (e,f) Hyperglycemic 
Sirt3+/+ mice had mildly reduced photopic b-wave implicit times compared to normoglycemic Sirt3+/+ mice. 
Although not statistically significant, there was a similar effect size in hyperglycemic versus normoglycemic 
Sirt3−/− mice (N = 8–12/group; 2-way mixed ANOVA). Graphs depict mean + S.E.M. (a–f).
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Sirt3−/−Sirt5+/−, and Sirt3+/−Sirt5−/− mice (Fig. 8a). When tested with ERG, hyperglycemic Sirt3−/−Sirt5−/− mice 
did not exhibit any retinal dysfunction in scotopic a-wave, scotopic b-wave, or photopic b-wave amplitudes at 
6 weeks following STZ induction compared to hyperglycemic littermate controls (Fig. 8b–d), consistent with 
absence of any gross changes in retinal morphology upon histological examination (Fig. 8e). Moreover, hypergly-
cemic Sirt3−/−Sirt5−/− mice did not show significant changes in a- or b-wave implicit times (Fig. 8f–h). However, 
hyperglycemic Sirt3−/−Sirt5−/− mice did exhibit reduced scotopic OP amplitudes compared to hyperglycemic 
Sirt3+/−Sirt5+/− littermate controls, indicative of inner retinal dysfunction, although photopic OP amplitudes 
were unchanged (Fig. 8i,j). These results suggest that SIRT3 and SIRT5 may play redundant, neuroprotective roles 
in the inner retina under hyperglycemic conditions.
Discussion
DR is a major cause of blindness in industrialized nations. Although therapies for DR largely focus on antago-
nizing VEGF to treat the vascular component of disease, there is increasing evidence that there is independent 
neuronal disease. Therefore, the motivation behind this study was to test whether there was a neuroprotective 
role for metabolic regulation via NAMPT-mediated NAD+ biosynthesis, SIRT3, or SIRT5 in a mouse model of 
type 1 diabetes. We have previously identified that NAMPT-mediated NAD+ biosynthesis is important for retinal 
energy homeostasis and that both SIRT3 and SIRT5 are important for protecting the retina against light-induced 
degeneration23,27. In the current study, we found that although these pathways have important roles in regulating 
some facets of retinal homeostasis, they individually play only minimal neuroprotective roles in retinopathy in 
a mouse model of type 1 diabetes. Moreover, SIRT3 and SIRT5 may have redundant roles in the inner retina and 
therefore possess the ability to functionally compensate for one another, as deletion of both was associated with 
modest, but significant, inner retinal dysfunction in the STZ-induced model of type 1 diabetes.
Although our findings are contrary to our original hypothesis, this study sheds important light on the patho-
physiology underlying retinal neuron dysfunction in DR and the role of metabolic regulation in this disease pro-
cess. NAMPT-mediated NAD+ biosynthesis has been reported to be essential in numerous cell types, including 
but not limited to rod and cone photoreceptors23, hippocampal and cortical excitatory neurons28, adipocytes29 
and skeletal muscle30. Many of these studies have examined animal phenotypes after cell-specific, biallelic Nampt 
Figure 6. (a–f) There were no significant differences in the scotopic a-wave, scotopic b-wave, or photopic 
b-wave implicit times when comparing hyperglycemic SIRT5 germline knockout (Sirt5−/−) and wild-type 
control (Sirt5+/+) mice to normoglycemic mice of the same genotype except for one pairwise comparison at a 
single flash intensity after post-hoc testing (N = 8–13/group; 2-way mixed ANOVA with Bonferroni post-hoc 
test). Graphs depict mean + S.E.M. (a–f) (^P < 0.0001).
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deletion using the Cre-lox system. Although these findings provide important insights that provide a foundation 
for future research, they also may not be a perfect model for what may be occurring in human disease when 
NAD+ homeostasis is perturbed, as they involve complete abrogation of an important cellular pathway. As such, 
we tested whether monoallelic Nampt deletion from rod photoreceptors was sufficient to render rod photore-
ceptors more vulnerable to dysfunction in a mouse model of diabetes. Our null results indicate that Nampt is hap-
losufficient in this disease context. These findings suggest that there is likely mitochondrial reserve that enables 
rod photoreceptors to maintain relative metabolic homeostasis even when challenged by partial disruptions in 
NAMPT-mediated NAD+ biosynthesis.
Furthermore, we found that germline deletion of neither SIRT3 nor SIRT5 individually affected the progres-
sion of retinal dysfunction in the STZ-induced model of type 1 diabetes, while combined germline deletion 
of both SIRT3 and SIRT5 was associated with inner retinal dysfunction under hyperglycemic conditions. In 
Figure 7. (a,b) There were no significant differences in scotopic oscillatory potential (OP) amplitudes between 
hyperglycemic SIRT3 germline knockout (Sirt3−/−) and wild-type control (Sirt3+/+) mice and normoglycemic 
mice of the same genotype except for one pairwise comparison at a single flash intensity after post-hoc 
testing (N = 8–12/group; 2-way mixed ANOVA with Bonferroni post-hoc test). (c,d) Although photopic OP 
amplitudes were significantly increased in hyperglycemic versus normoglycemic Sirt3−/− mice, we observed a 
similar pattern in hyperglycemic versus normoglycemic Sirt3+/+ mice (N = 8–12/group; 2-way mixed ANOVA). 
(e–h) There were no significant differences in scotopic or photopic OP amplitudes in hyperglycemic SIRT5 
germline knockout (Sirt5−/−) and wild-type control (Sirt5+/+) mice compared to normoglycemic mice of the 
same genotype (N = 8–13/group; 2-way mixed ANOVA). Graphs depict mean + S.E.M. (a–h) (RMS: root mean 
square; **P < 0.01).
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Figure 8. (a) SIRT3/SIRT5 double knockout mice (3KO5KO) were equally susceptible to streptozotocin 
(STZ)-induced hyperglycemia compared to littermate controls of various genotypes. (b–d) At 6 weeks after STZ 
induction, hyperglycemic 3KO5KO mice did not exhibit any retinal dysfunction based on their scotopic a-wave, 
scotopic b-wave, and photopic b-wave amplitudes compared to hyperglycemic littermate controls (N = 4–7/
group; 2-way mixed ANOVA). (e) Representative histological images show that hyperglycemic 3KO5KO 
mice did not exhibit any changes in retinal morphology compared to hyperglycemic littermate controls. (f–h) 
Hyperglycemic 3KO5KO mice did not have any significant changes in scotopic a-wave, scotopic b-wave, or 
photopic b-wave implicit times compared to hyperglycemic littermate controls (N = 4–7/group; 2-way mixed 
ANOVA). (i,j) Hyperglycemic 3KO5KO mice had significant reductions in scotopic but not photopic oscillatory 
potential (OP) amplitudes compared to hyperglycemic littermate controls (N = 4–7/group; 2-way mixed 
ANOVA with Bonferroni post-hoc test). Open circles depict individual mice (a); graphs depict mean ± S.E.M. 
(b–d, f–j) (RMS: root mean square; **P < 0.01; ***P < 0.001; red asterisks indicate significant differences 
compared to Sirt3+/−Sirt5+/− mice after post-hoc testing).
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contrast, single SIRT3 germline knockout mice themselves are more vulnerable to light-induced degeneration 
compared to wild-type controls27 and SIRT3/SIRT5 double knockout mice are even more vulnerable compared 
to either single knockout23. These contrasting findings confirm that although there are some similarities in the 
underlying pathophysiology modeled by light-induced degeneration and STZ-induced hyperglycemia, there are 
also differences in the cell stress and death pathways that are activated by photopic stimuli versus hyperglycemic 
stress. Although further studies are necessary to confirm our findings and to provide additional mechanistic 
insight, our study provides evidence that SIRT3 and SIRT5 may have redundant neuroprotective roles in the inner 
retina. These findings provide a foundation for future investigation aimed at developing sirtuin-based neuropro-
tection strategies for DR and other retinal neurodegenerative diseases.
Methods
Animals. All animal experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC) of Washington University in St. Louis and were performed in accordance with all relevant guidelines 
and regulations. We obtained Namptflox/flox mice from Dr. Shin-ichiro Imai31 and Rhodopsin-iCre75 transgenic 
mice from Dr. Ching-Kang Jason Chen32. We obtained Sirt3−/− and Sirt5−/− mice from Jackson Laboratories (Bar 
Harbor, ME) and bred them with the appropriate strain-matched, wild-type mice from Jackson Laboratories 
(129S1/SvImJ for Sirt3−/− and B6129SF2/J for Sirt5−/−). To induce systemic hyperglycemia, we injected mice 
daily for five days with 65 mg/kg body weight streptozotocin (STZ; Sigma, St. Louis, MO) freshly prepared in 
citrate buffer (0.10 M; pH 4.5) and compared hyperglycemic mice to vehicle-treated mice receiving citrate buffer 
alone. We measured blood glucose levels with the GLUCOCARD Vital (Arkray, Edina, MN) and weighed mice 
regularly, humanely euthanizing any mice exhibiting signs of diabetic ketoacidosis or other distress.
Electroretinography. We performed electroretinography (ERG) with the UTAS-E3000 Visual 
Electrodiagnostic System running EM for Windows (LKC Technologies, Gaithersburg, MD), as described previ-
ously23. We extracted quantitative measurements, such as a- and b-wave amplitudes and implicit times, from the 
ERG waveforms using a Microsoft Excel macro that defines the peak of the a-wave as the most negative point of 
the average trace and the peak of the b-wave as the most positive point without subtracting oscillatory potentials. 
To isolate oscillatory potentials, we used a custom script in MATLAB (Mathworks, Natick, MA) to digitally pro-
cess the ERG waveforms with a 25 Hz high-pass filter and calculated the root-mean-square (RMS) of the oscilla-
tory potentials after normalizing to b-wave amplitudes.
Immunoblotting. We compared SIRT3 and SIRT5 protein levels in STZ-induced hyperglycemic versus 
normoglycemic, wild-type control mice by Western blot. We loaded retinal lysate containing 15 μg protein into 
individual lanes, separated proteins using SDS-polyacrylamide gel electrophoresis, and then transferred them to 
a nitrocellulose membrane (0.2 μm, BIO-RAD, Hercules, CA). We then blocked membranes with 2.5% milk in 
1X PBS. Next, we incubated membranes at 4 °C overnight with a cocktail of primary antibodies containing 0.1% 
Tween-20 (v/v); a mouse monoclonal antibody against COX IV (Cell Signaling Technology #11967S, dilution 
1:1,000); and either a rabbit monoclonal antibody against SIRT3 (Cell Signaling Technology #5490S, dilution 
1:1,000) or a rabbit monoclonal antibody against SIRT5 (Cell Signaling Technology #8782, dilution 1:500). We 
then incubated membranes with a secondary antibody cocktail containing 0.1% Tween-20 (v/v); goat anti-mouse 
secondary antibody (IRDye 680CW, LI-COR, dilution 1:5,000); and goat anti-rabbit secondary antibody (IRDye 
800RD, LI-COR, dilution: 1:5,000). We visualized blots using an Odyssey CLx Imaging System and quantified 
protein bands of interest using Image Studio 4.0, normalizing to COX IV band intensity as a loading control. 
Protein expression of SIRT3 and SIRT5 in hyperglycemic, wild-type mice is provided as a ratio relative to expres-
sion in normoglycemic, wild-type mice.
Histology. After euthanizing the mice, we enucleated the eyes and fixed them in 4% glutaraldehyde for 
2 hours and then in 4% paraformaldehyde for 24 hours. Next, we embedded the eyes in methacrylate and pre-
pared six sections of 6–8 μm thickness cut through the optic nerve. We stained slides with H&E and acquired 
bright-field images with an Olympus BX51 microscope.
Statistics. We performed statistical analysis with Prism 5 (GraphPad, San Diego, CA), using the appropriate 
test for each data set. We considered P < 0.05 to be statistically significant. All data generated or analyzed during 
this study are included in this published article.
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